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Allogeneic adoptive cell transfer therapy as a potent universal 
treatment for cancer
Assaf Marcus, and Zelig Eshhar
Adoptive cell transfer (ACT), the transfer of 
therapeutic lymphocytes to patients, is a promising cancer 
treatment, with advances seen in patients with melanoma 
and neuroblastoma in early clinical trials [1, 2]. One type 
of ACT modality pioneered by our group relies on the use 
chimeric antigen receptors (CAR) redirected T cells [3, 
4]. CARs are typically composed of single chain antibody 
fragments fused to T cell activating signaling motifs, 
endowing the T cells with MHC unrestricted tumor 
specificity. One advantage of CARs over conventional 
TCRs is that costimulatory domains could be incorporated 
into the CAR endowing it with supra-physiological 
potency.
One limitation of ACT is the need to generate tumor 
specific lymphocytes for each individual patient, which is 
technically and economically challenging. We therefore 
sought to develop an approach for universal ACT, which 
would allow treatment of patients without the need for 
MHC matching [5]. We reasoned that because of their 
MHC  unrestricted  tumor  specificity,  allogeneic  CAR 
redirected T cells could be used as ‘universal effector 
cells’ against cancer in all patients. However, allogeneic 
adoptive transfer faces the problem of the host-versus-
graft response (HvG) and the danger of graft-versus-host-
disease (GvHD). 
We hypothesized that low dose irradiation would 
delay the rejection of allogeneic T cells and allow them 
enough time to destroy the tumor on one hand while on 
the other hand their eventual rejection would prevent the 
development of GvHD. Using this approach, fully MHC 
mismatched allogeneic T cells redirected with a HER2/neu 
specific CAR were able to provide as much therapeutic 
benefit as syngeneic cells in a model of metastatic disease. 
We demonstrated that the GvH reactivity of the allogeneic 
T cells caused extensive proliferation, augmenting the 
anti-tumor response, but that the allogeneic T cells were 
indeed eventually rejected and no GvHD developed. 
Our second working hypothesis was that modulating 
lymphocyte migration could potentially further increase 
therapeutic efficacy of allogeneic ACT. Both the HvG 
and GvH reactions originate in the lymph nodes where 
T cells encounter MHC mismatched antigen presenting 
cells (APC), undergo massive proliferation, and then 
egress out of the lymph nodes into peripheral organs. 
By contrast ACT introduces cells directly into the blood, 
circumventing egress, and allowing the cells to reach 
the tumor directly. We therefore surmised that blocking 
lymphocyte egress using the lymphocyte sequestering 
agent FTY720[6] might inhibit the HvG and GvH 
reactions to a much greater extent than the graft-versus-
tumor (GvT) reaction. Indeed, FTY720 enhanced the 
efficacy of allogeneic but not syngeneic ACT, such that 
allogeneic T cells provided superior therapeutic benefit 
over syngeneic ones with median survival of over one 
year and no manifestations of GvHD. 
In conclusion, our results suggest that MHC 
mismatched CAR redirected allogeneic T cells could 
function as ‘universal effector cells’, and could 
potentially be used as an ‘off-the-shelf’ cellular therapy 
of cancer. Blocking lymphocyte egress further increased 
the efficacy of the approach such that allogeneic cells 
were superior to syngeneic ones. This result conclusively 
demonstrates that we can harness the GvH reactivity of 
allogeneic T cells to augment the anti-tumor response 
without causing GvHD. While this work provides only a 
proof of principle, we strongly believe that this approach 
is widely applicable for two main reasons. First, by using 
other CAR, many different cancers could be targeted of 
both solid and hematologic malignancies [7]. Second, 
the HvG and GvH occur independently of the tumor, and 
since we were able to overcome this problem in our work, 
the same approach could be used regardless of tumor 
type. Taken together, our results suggests that with further 
tuning, allogeneic adoptive cell therapy may become the 
treatment of choice both because of its obvious technical 
and economical advantages and due to its greater efficacy.
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